UNSPSC 51101633: Amprolium

This classification denotes an antiparasitic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95CO6N199Q. European Medicines Agency schedules Amprolium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05489MIG. Amprolium generally arises in the molecular formula C14H19CLN4.

The term AMPROLIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) AMPROLIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amprolium under HS 29335995 and SITC 51576. As of Q4 2014, AMPROLIUM remains the US FDA Preferred Term for this commodity. Amprolium bears US NLM identifiers UMLS ID C0002686 and NCI Concept Code C76388. SMILES: [N]1(CC2C(NC(NC2)CCC)N)C(CCCC1)C.

UNSPSC 51101633 Amprolium is a Commodity code that captures antiparasitic pharmaceutical products state and local governments procure for public health and animal health supply programs. Recent opportunities tagged under this code show state and local agencies purchasing naloxone, drug deactivation systems, and antibiotic pharmaceuticals through cooperative purchasing vehicles and competitive bidding processes to support emergency response, community health, and disease prevention initiatives. The issuing bodies include state health departments and county government health and public safety divisions, which acquire these products as part of routine public health stockpiling and emergency preparedness operations.

Activity appears concentrated in Florida and Illinois. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC (Solicitation 26482DPHPREPDB53392, IFB, August 28, 2026, $2,999,999.11 over three years) for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets with 12-month initial term and renewal options. Seminole County, Florida released an IFB (IFB60459723LAS, posted June 30, 2026, response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract includes a two-year initial term with one-year renewal option and requires E-Verify compliance and standard insurance coverages. The Illinois opportunity leveraged cooperative purchasing, while the Seminole County procurement was direct competitive bidding with potential FEMA funding.